Constitutive overexpression of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is a key oncogenic event in anaplastic large-cell lymphomas with the characteristic chromosomal aberration t(2;5)(p23;q35). Proteins that interact with ALK tyrosine kinase play important roles in mediating downstream cellular signals, and are potential targets for novel therapies. Using a functional proteomic approach, we determined the identity of proteins that interact with the ALK tyrosine kinase by co-immunoprecipitation with anti-ALK antibody, followed by electrospray ionization and tandem mass spectrometry (MS/ MS). A total of 46 proteins were identified as unique to the ALK immunocomplex using monoclonal and polyclonal antibodies, while 11 proteins were identified in the NPM immunocomplex. Previously reported proteins in the ALK signal pathway were identified including PI3-K, Jak2, Jak3, Stat3, Grb2, IRS, and PLCc1. More importantly, many proteins previously not recognized to be associated with NPM-ALK, but with potential NPM-ALK interacting protein domains, were identified. These include adaptor molecules (SOCS, Rho-GTPase activating protein, RAB35), kinases (MEK kinase 1 and 4, PKC, MLCK, cyclin G-associated kinase, EphA1, JNK kinase, MAP kinase 1), phosphatases (meprin, PTPK, protein phosphatase 2 subunit), and heat shock proteins (Hsp60 precursor). Proteins identified by MS were confirmed by Western blotting and reciprocal immunoprecipitation. This study demonstrates the utility of antibody immunoprecipitation and subsequent peptide identification by tandem mass spectrometry for the elucidation of ALKbinding proteins, and its potential signal transduction pathways.
Introduction
Anaplastic large-cell lymphoma (ALCL) is a distinct subtype of peripheral T-cell lymphomas harboring chromosomal translocations involving the ALK tyrosine kinase (Stein et al., 1985; Mason et al., 1990) . The t(2;5)(p23;q35) chromosomal aberration resulting in overexpression of a chimeric oncogene, nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) (Morris et al., 1994; Shiota et al., 1994) , is the most common translocation found in these tumors. The resulting NPM-ALK fusion protein has been well documented as a constitutively active tyrosine kinase and the causative oncogene in t(2;5)-positive ALCLs Shiota and Mori, 1997) . The NPM-ALK protein plays a key role in ALCL lymphomagenesis, and has been shown to cause lymphoid malignancy in vitro and in vivo (Kuefer et al., 1997) .
The NPM-ALK fusion protein transduces its transforming capacity via several key signaling pathways including the PI3-K pathway leading to Akt activation , as well as activation of the JAK/ STAT pathway Zamo et al., 2002; Ruchatz et al., 2003) . The src homology SH2 and phosphotyrosine-binding (PTB) protein motifs within the cytoplasmic domain of ALK are known to mediate its interaction with other signaling molecules . Co-immunoprecipitation studies have demonstrated the interaction of ALK with PLCg (Bai et al., 1998) , IRS-1 (Fujimoto et al., 1996) , Hsp90 (Bonvini et al., 2002) , Grb, ShcC (Miyake et al., 2002) , Jak3 (Zamo et al., 2002) , Jak2 (Ruchatz et al., 2003) , Stat5 (Nieborowska-Skorska et al., 2001) , and Stat3 (Zamo et al., 2002; Zhang et al., 2002) .
In many instances, it has been well established that proteins do not act alone but form multimeric complexes with potential substrates and regulatory proteins that influence its biologic activity (Edmondson et al., 2002) . Since ALK plays a critical role in the activation of multiple signaling pathways, determination of its interacting proteins and those that form the complex of proteins within its 'interactome' may provide novel insights as to its function, as well as reveal potential targets for novel therapies.
The emerging field of proteomics provides a powerful avenue to carry out functional studies of proteinprotein interactions and characterization of signal transduction pathways (Figeys et al., 2001; Shiio et al., 2002) . This is in large part due to advances in protein sample preparation, analytical sensitivity of mass spectrometers (Blagoev et al., 2003; Peng et al., 2003) , and improvements in instrument software and protein databases (Edmondson et al., 2002; Ranish et al., 2003) . Until recently, assessment of interacting proteins has only been feasible via laborious and time-consuming molecular biologic techniques such as the yeasttwo-hybrid system. Using a variety of approaches including protein complex purification, immunoprecipitation, affinity chromatography followed by highperformance liquid chromatography (HPLC), and electrospray ionization and tandem mass spectrometry (ESI-MS/MS), interacting proteins of CD4 receptor complex (Bernhard et al., 2003) , nonmuscle myosin heavy chain-IIA (Rey et al., 2002) , proliferating cell nuclear antigen (Ohta et al., 2002) , protein kinase Ce signaling complex (Edmondson et al., 2002) , and apolipoprotein B (Rashid et al., 2002) have been identified, to list a few. Although the specific nature of the protein interactions needs to be functionally validated, these approaches represent a high-throughput method for the identification of proteins within a complex, and provide insights into the fundamental basis of their biologic activities.
In this study, we sought to determine the identity of proteins that interact with NPM-ALK tyrosine kinase using immunoprecipitation, followed by liquid chromatography (LC) and ESI-MS/MS (Figure 1 ). In addition to confirming the identity of previously reported proteins in the ALK signal pathway including phospholipase C-gamma (PLCg1) (Bai et al., 1998) , phosphoinositide-3-kinase (PI3-K) (Bai et al., 2000; Slupianek et al., 2001) , Jak2 (Ruchatz et al., 2003) , Jak3 (Zamo et al., 2002) , and IRS , we have identified a comprehensive list of proteins that may represent novel mediators of ALK signaling. This study demonstrates the utility of antibody immunoprecipitation and peptide identification by nanoflow ESI-LC/MS/MS for the high-throughput identification of proteins within the ALK signaling complex and potential definition of its signaling pathways.
Results

Expression of NPM-ALK in t(2;5)-positive cell lines
To determine the basal level of expression of the NPM-ALK fusion protein in a t(2;5)-positive cell line Karpas 299 and the t(2;5)-negative cell line Mac 2A, we performed Western blot analysis of total cell lysates and probed with an anti-ALK antibody (Figure 2 ). The 80 kDa NPM-ALK fusion protein is expressed in the Karpas 299 cell line, but not in Mac 2A.
Immunoprecipitation with anti-ALK antibody
To determine the complexes of proteins associated with the NPM-ALK tyrosine kinase, we performed immunoprecipitation of total cell lysate obtained from Karpas 299 cells using both monoclonal and polyclonal anti-ALK antibodies. Figure 3a demonstrates separation of the ALK immunocomplex by 1-dimensional-SDS-PAGE in the Karpas 299 cells, with subsequent silver staining of the separated proteins. Immunoprecipitation using a control IgG antibody was also 
MS/MS sequencing of peptides
The excised protein bands were prepared for the mass spectrometer by destaining, and overnight in-gel digestion followed by peptide extraction and reduction in volume by vacuum centrifugation. Using data-dependent scanning, the mass spectrometer was set to cycle from 400 to 2000 amu, followed by MS/MS scans of the top three most abundant ions. Dynamic exclusion was used to acquire a more complete survey of the peptides contained in the immunocomplex by automatic recognition and exclusion of an ion, from which definitive mass spectral data had previously been acquired. Analysis of the SDS-PAGE lanes obtained from the anti-ALK immunocomplex resulted in a total of 297 peptides, which were matched to 188 known database entries and 57 unique proteins. The peptides ranged in length from six to 28 amino-acid residues, with the average size of identified peptides at 14 amino-acid residues. The chance of an exact match between two peptide sequences, which are 14 amino acids in length, using . This calculation provides significant credence to the identity of the matched proteins. Multiple peptides corresponding to the same protein further strengthened the identification. In addition, the analysis of NPM-ALK interacting proteins was comparable in a second NPM-ALK positive cell line, SUDHL-1 (data not shown). Figure 4 displays the total ion chromatogram (TIC), followed by MS and MS/MS scans of the dominant ions from three selected proteins: (A) ALK, (B) PI3-K, and (C) MEK kinase 1. The peptide sequence coverage identified by MS/MS is represented for each protein.
The TIC displays the ion trap scans for the 60 min HPLC gradient, with the y-axis scaled (100% response) to the most abundant peak seen during the 1-h analysis. Peptide elution can be seen just prior to 30 min. The TIC window is followed by the chromatogram for datadependent acquisition of a top MS full scan peak, which in turn triggers the MS/MS scanning of that same mass ion. Peptide sequence information is then extracted and matched to protein entries in the database.
Preliminary evaluation of the proteins identified in the NPM-ALK immunocomplex revealed an abundance of cytoskeletal proteins such as cytokeratin, myosin, and tubulin. Interestingly, several peptides identifying 'unknown' or 'novel' protein entries in the NCBI database were carefully searched for conserved motif or conserved domain amino-acid sequence information (http:// www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml). These novel proteins were closely related to filament, cytokeratin or other structural proteins, and were not pursued further. The IgG light-chain and heavy-chain proteins observed in the silver-stained gel of the immunoprecipitation ( Figure 3 ) were also identified by MS (data not shown). However, in order to maximize the likelihood for the identification of low abundance proteins, subset databases were created and used to search for targets 'underneath' the abundant proteins first identified. Table 1 summarizes the four databases used for comprehensive peptide searching, as well as the number of proteins identified by each targeted database.
Unique proteins identified by ALK immunoprecipitation
To select for proteins that interact specifically with the NPM-ALK protein and not those that associate with the IgG in a nonspecific manner, we substracted those proteins that were common between the IgG control immunoprecipitation lane (data not shown) and the ALK immunocomplex lanes. Proteins were determined to be potential interacting proteins of NPM-ALK, only after subtracting those proteins identified from the corresponding kDa gel slices in the IgG immunoprecipitation lane.
Tandem mass spectrometric analysis of the monoclonal anti-ALK immunocomplex identifed 18 potential interacting proteins. Analysis of the polyclonal anti-ALK immunocomplex identified 30 proteins. In all, 12 proteins were identified in both monoclonal and polyclonal ALK immunocomplexes (proteins identified with asterisk). The proteins, their NCBI gene identification numbers (gi#), molecular weights, percentage of peptide coverage seen over the entire amino-acid sequence, and the NCBI conserved domains are summarized in Table 2 . For reproducibility, only those proteins identified in all immunoprecipitation experiments were included in the final summary.
Analysis of proteins in Table 2 shows that NPM and ALK are identified in both monoclonal and polyclonal anti-ALK immunocomplexes. Additionally, the proteins could be categorized into several functional groups: adaptor molecules (Grb2, SOCS1, SOCS5, IRS4, RhoGTPase-activating protein, RAB35,) kinases (MAP kinase 1, MEK kinase 1,4 and 5, PKC, MLCK, EphA1, ephrinB, JNK kinase 2, cyclin G-associated kinase), phosphatases (meprin, PTPK, protein phosphatase 2 subunit), and heat shock proteins (Hsp60 precursor). As shown in Table 2 , many of the listed proteins have protein domains that could potentially mediate interactions with the SH2 and PTB motifs of the cytoplasmic domain of ALK.
Importantly, several proteins that have been previously reported to interact with NPM-ALK such as PI3-kinase, PLCg1, Jak2, Jak3, Stat3, and IRS were identified (Table 2 ). Interestingly, proteins that bind to components of nuclear matrix such as lamin B1 (Luderus et al., 1992) , centromere proteins (Payen et al., 1998) , and RAD17 homolog (Kai et al., 2001) were also identified. A subset of these proteins may represent proteins that interact with the nucleophosmin component of the NPM-ALK fusion protein. Indeed, centromere protein F was identified in the anti-NPM immunocomplex (Table 3) .
Unique proteins identified by NPM immunoprecipitation
During the t(2;5) translocation event, the amino-acid residues 118-294, including the carboxy terminus of nucleophosmin, are cleaved. The NPM-ALK chimeric fusion contains only the amino-terminal amino-acid residues 1-117 of NPM (Shipp et al., 2002) . Our mass spectrometric analysis identified 11 proteins within the anti-NPM immunocomplex (Table 3) . These included CDC14, which is associated with the centrosome structure (Kaiser et al., 2002) , NUP98, a nucleoporin (Griffis et al., 2003) , NuMA which is a nuclear matrix protein associated with the mitotic apparatus (Taimen et al., 2000) , and SNF2, a chromatin-remodeling ATPase (Rossi et al., 2003) . Interestingly, two proteins (Grb2 and centromere protein F) were identified in both anti-ALK and anti-NPM immunoprecipitates. This may indicate that some novel protein-protein interactions result from the fusion kinase proximity of the NPM and ALK conserved domains.
Validation of MS/MS peptide identification by Western blot analysis
In order to validate the proteins identified by MS/MS peptide matching, we performed Western blot analysis on both the total cell lysates and the ALK immunoprecipitates of the t(2;5)-positive cell line Karpas Proteomic analysis of NPM-ALK interacting proteins DK Crockett et al 299 and the t(2;5)-negative cell line, Mac 2A. We selected PLCg1 which has been previously reported to interact with NPM-ALK, and three proteins that represent novel ALK-interacting proteins, PKC, MEK kinase 1, and EphA1. As shown in Figure 5 , the expression of NPM-ALK, PLCg1, and EphA1 was observed in both the total cell lysate and the ALK immunocomplexes of the t(2;5)-positive ALK-positive cell line specifically. The identification of PKC and MEK kinase 1 in the total cell lysate, but not the ALK immunoprecipitate of the t(2;5)-negative Mac 2A cell line, provides additional evidence for the specificity of the ALK association of proteins such as PLCg1 and EphA1, which were identified exclusively in the ALK 'pull downs' from the t(2;5)-positive (Karpas 299) cell lines. 
Validation by reciprocal immunoprecipitation
To further verify the interaction between NPM-ALK and those proteins identified by mass spectrometry, we performed reciprocal immunoprecipitation using antibodies against a total of eight proteins, of which three are known interacting proteins (Grb2, Stat3, and IRS1), and five are novel interacting proteins (Hsp60, elF4B, EphA1, ephrinB, and MEK kinase 1) identified by our current study. As shown in Figure 6 , Western blot analyses of the various immunocomplexes with an anti-ALK antibody demonstrated the association of these proteins with NPM-ALK. This provides additonal evidence for the in vivo 
Discussion
The t(2;5)(p23;q35) chromosomal aberration and the subsequent chimeric NPM-ALK oncogene (Morris et al., 1994; Shiota et al., 1994) lead to constitutive activation of the ALK tyrosine kinase (Morris et al., 1997; Shiota (Zamo et al., 2002; Zhang et al., 2002) . This study represents the first global, high-throughput functional proteomic study to determine the identity of proteins that may form a multimeric complex with the NPM-ALK tyrosine kinase. We used immunoprecipitation followed by LC and electrospray ionization (ESI) tandem mass spectrometry (MS/MS). Similar approaches have been used by others to determine the interacting proteins of various targets (Edmondson et al., 2002; Ohta et al., 2002; Rashid et al., 2002; Rey et al., 2002; Bernhard et al., 2003) .
Our analysis of the ALK immunocomplex revealed a total of 89 proteins. After subtracting those proteins found within the IgG control lanes, 46 unique proteins were identified. Notably, we identified several proteins that had been previously reported to bind to NPM-ALK, such as Grb2, IRS, Jak2, Jak3, Stat3, PLCg1, and PI3-K. The remaining proteins represent novel interacting proteins that may form a multimeric complex with NPM-ALK. These may be proteins that interact with NPM-ALK in a direct manner and possibly represent substrates of ALK, or regulatory proteins that modulate the activity of ALK such as phosphatases. Additionally, they may be proteins that do not directly interact with NPM-ALK but bind to its substrates or regulators.
Analysis of the protein identities and their protein domains (Table 2) suggests several potential phosphatases (meprin, PTPK, protein phosphatase 2 subunit) which may regulate the kinase activity of ALK. To date, no endogenous phosphatase has been identified that may regulate the activity of ALK. One of these proteins, the protein phosphatase 2 subunit (PP2A), has been shown to bind to activated Stat3 in ALK-positive cell lines , suggesting that the proteins identified by our method include both direct and indirect mediators of ALK activity.
Adaptor molecules such as SOCS, IRS4, RhoGTPase-activating protein, and RAB35 implicate the Ras/MAPK kinase pathway in ALK-mediated oncogenesis. Although the Ras/MAPK pathway has not been previously implicated in ALK-mediated oncogenesis, it was shown to be activated upon stimulation of the full-length ALK receptor in neuronal cells (Souttou et al., 2001) . The identification of proteins of the Ras family (RAB35, rho-GTPase-activating protein), JIP3 (Kelkar et al., 2000) MEK kinase 1, and MEK kinase 4 suggests that the Ras/MAPK pathway may also be involved in NPM-ALK-mediated oncogenesis. The identification of kinases such as MEK kinase 1, PKC, MLCK, and EphA1 receptor tyrosine kinase raises the hypothesis that these proteins may be either substrates of ALK, or potential regulators of ALK. Interestingly, EphA1, a receptor tyrosine kinase whose expression is normally restricted to stem cells and cells of the nervous system (Tessier-Lavigne, 1995) , is also overexpressed in a subset of human epithelial malignancies (WalkerDaniels et al., 1999; Zelinski et al., 2001 ) and T cells (Sharfe et al., 2003) . More interestingly, EphA tyrosine kinase can stimulate PI3-K activity (Pandey et al., 1994) , as well as the MAP/ERK kinase signaling cascade (Pratt and Kinch, 2002) , suggesting that its presence in the NPM-ALK signal complex may occur via either direct interaction with NPM-ALK itself or via indirect interactions with PI3-K, or components of the MAP/ ERK pathway. Due to the translocation event, amino-acid residues 118-294, as well as the carboxy terminus of nucleophosmin, are not present in the NPM-ALK fusion protein (Shipp et al., 2002) . Proteins found in common between the anti-ALK immunocomplex and the anti-NPM (amino terminus) immunocomplex can therefore be attributed to the NPM component of the chimeric fusion. By utilizing an antibody specific to the amino terminus of NPM, we indentified 11 proteins with potential interactions with the NPM component of the ALK fusion protein. Importantly, nucleophosmin, Grb2, and centromere protein F were identified in both the anti-ALK immunoprecipitate and anti-NPM immunoprecipitate. Furthermore, the detection of proteins involved in centrosome organization (CDC14) (Kaiser et al., 2002) , nuclear pore membranes (NUP98) (Griffis et al., 2003) , mitotic apparatus (NuMA) (Taimen et al., 2000) , and chromatin remodeling (SNF2) (Rossi et al., 2003) provides further support for the functional specificity of the immunoprecipitations used for the study.
Validation of the proteins identification by Western blot analyses demonstrated that, although PKC and MEK kinase 1 were expressed in both ALKpositive and ALK-negative cell lines, their co-immunoprecipitation with ALK implicates a significant role in the signal transduction pathway of NPM-ALK. The observation that PLCg and EphA1 were only expressed in the ALK-positive cell lines suggests that they may play a specific role in the pathogenesis of ALK-positive ALCLs.
Our identification of several known members of the insulin receptor signaling pathway, for example, insulinlike factor 6, IPT3, insulin promoter factor 1, IRS4, and PI3-K, is not surprising, given that ALK is a member of the insulin receptor family (Morris et al., 1994) . Although IRS1 has been implicated in NPM-ALK lymphomas, the role of the other proteins in the signaling pathway remains to be determined. The identification of proteins associated with the cytoskeleton such as myosin-binding protein is also interesting in the context of the diverse consequences of NPM-ALK signaling. Indeed, cytoskeletal proteins such as myosin have been implicated in cell signaling (Baba et al., 2003) in other cell systems. The finding of heat shock proteins (Hsp60 precursor) as a potential interacting partner of NPM-ALK is also of interest, as NPM-ALK has been shown to be a client protein of the chaperone protein Hsp90 (Bonvini et al., 2002) .
The large number of proteins that were identified within the NPM-ALK signaling complex was initially quite surprising. It is generally thought that protein kinases do not form stable complexes with their substrates, as rapid on/off rates for phosphorylation are essential for signaling kinases to function effectively as critical signaling mediators in cells. However, studies have demonstrated that certain protein kinases such as PKB (AKT) can exist in a stable complex with several of its substrate proteins, and can also interact with many proteins that do not serve as substrates, but rather play a regulatory role in its function (Brazil et al., 2002) . Recent studies using hammerhead ribozymes to target the NPM-ALK transcript (Hubinger et al., 2003) have shown that the half-life of the NPM-ALK fusion protein may be greater than 48 h. Given this extremely long halflife, NPM-ALK may exist in a very stable complex with its interacting proteins. Furthermore, functional proteomic studies of the protein kinase C e signaling complex have also revealed a large number of proteins (87), including a diverse complement of proteins involved in metabolism, transcription, and translation (Edmondson et al., 2002) .
The MS/MS search strategy of using targeted database subsets proved invaluable in constructing a complete survey of NPM-ALK-interacting proteins. The full NCBI nonredundant database contains more than 1.8 million protein entries. The chance of identifying low-abundance proteins such as cell-signaling Figure 6 Reciprocal immunoprecipitation (IP) of Karpas 299 cell lysate using anti-Hsp60, anti-Grb2, anti-Stat3, anti-IRS1, antielF4B, anti-EphA1, anti-ephrin B, and anti-MEK kinase 1, followed by Western blot analysis (WB) with anti-ALK antibody, demonstrates the interaction of NPM-ALK with these selected proteins Proteomic analysis of NPM-ALK interacting proteins DK Crockett et al molecules in the entire database is relatively poor. By employing a search strategy that excluded the first tier of easily identified proteins, we were able to 'drill down' into the MS/MS data and identify additional proteins that were subsequently validated by reciprocal immunoprecipitation or Western blot analyses. We acknowledge that nonspecific binding is possible when using polyclonal antibody immunoprecipitation as a technique for sample enrichment, thus identifying false protein interactions. However, a careful review of the literature for NPM-ALK interactions revealed that the majority of the published studies utilized polyclonal antibodies in their experimental design (Fujimoto et al., 1996; Bai et al., 1998 Bai et al., , 2000 Hubinger et al., 1999; Lux et al., 1999; Nieborowska-Skorska et al., 2001; Slupianek et al., 2001; Bonvini et al., 2002; Miyake et al., 2002; Raetz et al., 2002; Zamo et al., 2002; Zhang et al., 2002; Amin et al., 2003; Baba et al., 2003; Khoury et al., 2003; Ruchatz et al., 2003) . In this regard, we have chosen to categorize proteins identified using both monoclonal and polyclonal antibodies. We found that the overall yield of the polyclonal immunocomplex was consistently higher, as seen by silver stain band intensity. One could argue the possibility of nonspecific binding, and thus false protein interactions. However, the higher concentration of the immunocomplex could also be the reason for more proteins being identified when using polyclonal immunoprecipitation. Of note, the difficulty of analysing the stoichiometric nature of protein binding and transient environment of protein interactions is further compounded by the random sampling of peptides during 'data-dependent' analysis by mass spectrometry. To illustrate this difficulty, two well-known NPM-ALK interacting proteins (IRS and PLCg1) were seen only in the polyclonal immunocomplex, and not found in the monclonal immunocomplexes. Therefore, in addition to the cautious selection of controls, reproducible experiments are key to eliminating false-positive identifications.
In summary, we present a high-throughput functional proteomic approach to identify a complex of proteins that interact with the NPM-ALK fusion protein. Our results demonstrate that a large number of proteins are in close proximity to the oncogenic tyrosine kinase, and support the growing body of evidence that proteins do indeed work in multimeric complexes mediating various signaling cascades. The experimental strategy used in this study could also be adapted to investigate the celltype specificity of binding proteins in tumors with ALKfusion partners other than NPM.
Materials and methods
Cell culture
Human lymphoma cell lines were obtained from American Type Culture Collection (Rockville, MD, USA). All cell lines were maintained in RPMI 1640 medium (Novatech, Inc.) supplemented with 10% heat-inactivated fetal calf serum, and antibiotic mixture (Gibco-BRL). Karpas 299 and SUDHL-1 were derived from ALCL, which have the t(2;5)(p23;q35) translocation, resulting in the NPM-ALK fusion gene (Epstein and Kaplan, 1974; Fischer et al., 1988) . Mac 2A was derived from a cutaneous T-cell lymphoma (CTCL), and represents a CD30 þ ALCL lacking the t(2;5) translocation (Davis et al., 1992; Knaus et al., 1996) . Each cell line was grown to confluency, and samples (approximately 10 7 cells each) were pelleted and stored at À801C.
Cell lysis, immunoprecipitation, and Western blot analysis
Cells were lysed using 0.5. ml RIPA buffer (25 mM Tris-HCl, 0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate, 0.15 M NaCl, 1 mM EDTA) per pellet. Before each use, 0.1% protease inhibitor cocktail (Sigma) was added to the required volume of RIPA buffer. Protein concentrations were estimated using the Bradford colorimetric method against known concentrations of BSA. Lysate from two to three cell pellets was combined to obtain the desired concentration of 3-4 mg/ml of total protein for each cell line.
For immunoblotting, lysates containing 40 mg of total protein (per lane) were resolved in a 10% SDS-PAGE. Separated proteins were then transferred to a nitrocellulose membrane filter (Millipore) using semi-dry transfer, and blocked overnight at 41C with 5% milk. The membrane was incubated at room temperature with the appropriate dilution of primary antibody, then washed and incubated with horseradish peroxidase-conjugated secondary antibodies. Western blot targets were visualized using enzyme chemiluminescence (ECL Plus kit, Amersham). The following antibodies were used for immunoblotting analysis: mouse monoclonal antibody ALK (Zymed), rabbit polyclonal antibodies PKC (H-300), PLCg1 (530), EphA1 (G-18), and MEK kinase-1 (C-22), and goat polyclonal antibodies ALK (C-19) and actin (H-196) (Santa Cruz Biotechnology).
For immunoprecipitation, lysate containing 800-1000 mg of total protein was precleared using the appropriate isotype IgG antibody, mixed with 2 mg of primary antibody, then incubated with gentle shaking overnight at 41C. Protein G agarose was added to each tube and the samples incubated again with gentle shaking at 41C. The immunocomplex was washed with cold RIPA buffer and the antibody-selected proteins were eluted from the agarose beads by boiling in SDS-loading buffer (0.1 M Tris-HCl, 10% glycerol, 2% SDS, 0.05% bromophenol blue, and 0.1 M DTT) for 5 min. Each sample was resolved on a 10% SDS-PAGE and visualized with mass spectrometry-compatible silver staining (Invitrogen). Similar conditions with appropriate IgG antibody (Santa Cruz) were used for the control lane of each gel. The following antibodies were used for immunoprecipitation: mouse monoclonal antibodies ALK and NPM (Zymed), rabbit polyclonal antibodies elF4B, Grb2, and Stat3 (Cell Signaling Technologies), nucleophosmin (H-106), ephrin B (A-20), and MEK kinase-1 (C-22) (Santa Cruz Biotechnology), and goat polyclonal antibodies ALK , and actin (H-196) (Santa Cruz Biotechnology). Immunoprecipitation using the monoclonal antibodies was performed in duplicate. Immunoprecipitation using the polyclonal antibodies were performed in triplicate.
Tryptic digestion, peptide extraction, and mass spectrometric analysis After silver staining the gel, bands of interest were excised, destained, digested, and extracted using the Invitrogen protocol. Briefly, each band is destained and washed, crushed and dried, and then rehydrated in ammonium carbonate buffer. A 100 ml aliquot (12.5 ng/ml) of freshly prepared trypsin (Promega) was added to each tube, and the tubes incubated overnight at 371C. The digested peptides were extracted from the gel pieces with 50% acetonitrile with 0.1% trifluoroacetic acid (TFA), and reduced to a final volume of 20-25 ml. A 10 ml aliquot of each sample was analysed by automated nanoflow reverse-phase LC/MS, using the LCQ Deca XP ion-trap mass spectrometer (ThermoFinnigan). Digested peptides were injected by an autosampler, using an acetonitrile gradient (0-60% B in 30 min; A ¼ 5% acetonitrile with 0.4% acetic acid and 0.005% heptafluorobutyric acid (HFBA), B ¼ 95% acetonitrile, 0.4% acetic acid, and 0.005% HFBA) through a reverse-phase column (75 mm ID fused silica packed with 10 cm of 5 mm C18 particles) to elute the peptides at a flow rate of 200 nl/min into the mass spectrometer. An electrospray voltage of 1.8 kV was used with the ion-transfer tube temperature set to 2001C. Peptide analysis was performed using data-dependent acquisition of one MS scan (400-2000 amu), followed by MS/MS scans of the three most abundant ions in each MS scan. To obtain better peptide coverage, dynamic exclusion was set to a repeat count of 2, with the exclusion duration of 1 min. Due to the complex nature of the protein samples, and differences in instrumentation and software, no single threshold is standard for scoring protein identification. From experience, we chose a SEQUEST cross-correlation score (X corr ) of 2.0 or greater to be considered as a potential match. For confident identification of proteins, additional factors were taken into consideration, such as the number of unique peptides found per protein, the total number of matching y-and b-series ions, the delta correlation score (DC n ) from the next nearest hit, any known conserved domain protein interactions, and feasible molecular signal transduction interactions.
Database search strategies
The MS/MS acquired data were searched with TurboSequest s against amino-acid sequences in the National Center for Biotechnology Information nonredundant (NCBInr) protein database (7.8.2003 download) . The peptide-matching criteria of a cross-correlation score (X corr )42.0, and a delta correlation score (DC n )40.100 with a minimum of two peptides per protein was used as a threshold of acceptance. When at least two peptides met these requirements per protein, additional peptides were then included to maximize the peptide coverage of the identification.
To better focus the peptide searching, an intermediate database (human.fasta) of only human proteins was extracted from the entire NCBI nonredundant database. Additionally, a database excluding keratin and cytokeratin (human_noker-atin.fasta) was extracted from the human protein only database. Finally, a comprehensive list of potential NPM-ALK interacting proteins was gathered from reviewing literature and used to build the last database (alk_pathway. fasta) from the human subset of the NCBI nonredundant protein database. Search parameters for each gel band were initially set quite relaxed, and then more strict for subsequent searches. To increase the confidence of protein identification, searching for tryptic, partially tryptic, and nontryptic fragments was performed and, to validate promising protein candidates, search results from all the four databases were compared.
